ArticleDatabase : the journal of biological databases and curation2025
Navigating open-source waters: the pharmaceutical industry's role in bioontology development.
Article in Database : the journal of biological databases and curation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An informatics framework to harmonize electronic health record medication data for managed care analytics and artificial intelligence applications.Journal of managed care & specialty pharmacy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioontologies are core to many data management strategies, artificial intelligence and machine learning initiatives, and search functionality within many pharmaceutical companies. Despite their integral role, many bioontologies, along with their associated tools, are maintained predominantly by academia and their partners, government supported initiatives, and the general community. In this comment, we will dive into some of the reasons behind this trend and argue that there exists a mutual advantage for the life science industry, and pharmaceutical companies in particular, to actively contribute to the advancement of public ontologies and open-source tools. This benefit extends beyond ethical and moral considerations and aligns with strategic interests. Additionally, we will explore practical approaches for contributing, sharing our (Novo Nordisk's research and early development) experience in doing so.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.